• About
• Links
• Contact
• Sitemap

Cancer Therapeutics Markets

Cancer is the second leading cause of death by disease in the United States, exceeded only by heart disease. Traditionally cancer has been treated with surgery, chemotherapy, hormones and radiation therapy, alone or in combination. Emerging technologies include photodynamic therapy, gene therapy, biological therapy (immunotherapy) and angiogenesis inhibitors.

Pharmaceutical and biotechnology companies are investing billions of dollars to search out and develop weapons for the arsenal in the war against cancer. This report provides an overview of the global market for cancer therapeutics.

The examination focuses on the efforts of biotechnology companies and pharmaceutical firms to incorporate new technologies for developing anti-cancer drugs into their corporate strategies. This study examines cancer therapeutic products now on the market, as well as those currently under development that might be commercialized in the near future. Additionally, the report profiles a number of firms that are actively involved in marketing and developing of products to be used in the treatment of cancer-both large multinational corporations.

The analysis also provides an overview of the disease and data on cancers by site or type. It provides incidence and mortality data for different types of the disease. In addition, the report provides a summary of each of the therapies that are being used to treat cancer.

Table of Contents

• 1. Overview5
  • 1.1Introduction5
  • 1.2Goals and Objectives6
  • 1.3Study, Scope and Format6
  • 1.4Methodology6
  • 1.5Summary of Major Findings8
  
  
• 2.Introduction to the Cancer Therapeutic Market10


• 3.Cancer Therapeutics Market Overview18
  • 3.1Cancer Therapeutics in the Pharmaceutical and Biotech Industry18
  • 3.2Business Analysis of the Cancer Market25
    • 3.2.1Growth Potential25
    • 3.2.2Demographics of Cancer26
    • 3.2.3The Global Market for Cancer Therapies26
      • 3.2.3.1European Cancer Market28
      • 3.2.3.2The Environment in the U.K. for Clinical Research into New Anti-Cancer Therapies30
      • 3.2.3.3The Suitability of Current U.K. and E.U. Regulatory Regimes30
      • 3.2.3.4Comments on the Current E.U. Regulatory Environment31
  • 3.3The Pharmaceutical Industry32
  • 3.4Cancer Therapies33
    • 3.4.1Market Size33
  • 3.5New Product Trends35
    • 3.5.1Chemotherapy35
    • 3.5.2Hormone Therapy40
    • 3.5.3Photodynamic Therapy and Photosensitizers41
    • 3.5.4Gene Therapy41
      • 3.5.4.1Tumor-Suppressor Gene Therapy42
      • 3.5.4.2Immunomodulatory Gene Therapy42
      • 3.5.4.3Suicide Gene Therapy42
    • 3.5.5Radiation Therapy43
    • 3.5.6Farnesyl Transferase Inhibitors (FTIs)44
    • 3.5.7Genetic Screening44
    • 3.5.8Biological Therapies45
    • 3.5.9Interferons46
    • 3.5.10Interleukins46
    • 3.5.11Tumor Necrosis Factor (TNF)46
    • 3.5.12Colony-Stimulating Factors (CSFs)46
    • 3.5.13 Monoclonal Antibodies (MAbs)47
    • 3.5.14Cancer Vaccines48
    • 3.5.15Anti-Sense Therapy50
    • 3.5.16Adjuvants50
    • 3.5.17Angiogenesis Inhibitors51
    • 3.5.18Hyperthermia53
    • 3.5.19Transplants53
      • 3.5.19.1Bone Marrow Transplants53
      • 3.5.19.2Stem Cell Transplants53
      
      
• 4.The Disease of Cancer56
  • 4.1Incidence of Cancer56
    • 4.1.1U.S. Statistics56
    • 4.1.2Global Statistics58
  • 4.2Causes of Cancer61
  • 4.3Risk Factors62
    • 4.3.1Smoking63
    • 4.3.2Diet63
    • 4.3.3Radiation63
    • 4.3.4Occupational Risks64
    • 4.3.5Medicine and Infection65
    • 4.3.6Environmental Pollution65
    • 4.3.7Reproductive Factors65
    • 4.3.8Socio-Economic Factors65
  • 4.4Cancer Costs66
  
  
• 5.Specific Cancers67
  • 5.1Bladder Cancer67
    • 5.1.1Overview of the Disease67
    • 5.1.2Diagnosis and Staging68
    • 5.1.3Therapy68
    • 5.1.4Test for Bladder Cancer Analyzes DNA in Urine70
    • 5.1.5Drugs in Development71
  • 5.2Brain Cancer71
    • 5.2.1Overview of the Disease71
    • 5.2.2Treatment Options72
  • 5.3Breast Cancer73
    • 5.3.1Overview of the Disease73
    • 5.3.2Therapeutic Drugs74
    • 5.3.3Market Overview for Breast Cancer Therapeutics89
  • 5.4Cervical Cancer91
    • 5.4.1Overview of the Disease91
    • 5.4.2Treatment Options92
  • 5.5Colon Cancer94
    • 5.5.1Overview of the Disease94
    • 5.5.2Treatment Options94
    • 5.5.3Market Overview for Colon Cancer Therapeutics100
  • 5.6Leukemia101
    • 5.6.1Overview of the Disease101
    • 5.6.2Treatment Options102
  • 5.7Lymphoma108
    • 5.7.1Overview of the Disease108
    • 5.7.2Treatment Options108
  • 5.8Lung Cancer112
    • 5.8.1Overview of the Disease113
    • 5.8.2Treatment Options113
    • 5.8.3Breakthrough Treatments for Lung Cancer114
    • 5.8.4Market Overview for Lung Cancer Therapeutics123
  • 5.9Ovarian Cancer123
    • 5.9.1Overview of the Disease124
    • 5.9.2Treatment Options124
  • 5.10Prostate Cancer132
    • 5.10.1Overview of the Disease132
    • 5.10.2Treatment Options132
    
    
• 6.Corporate Profiles137
  • 6.1AstraZeneca Plc137
  • 6.2Biogen Idec, Inc.138
  • 6.3Bristol-Myers Squibb139
  • 6.4Genentech, Inc.140
  • 6.5Genta, Inc.142
  • 6.6Genzyme Oncology142
  • 6.7GlaxoSmithKline Plc143
  • 6.8ImClone Systems, Inc.144
  • 6.9 Medarex146
  • 6.10Millennium Pharmaceuticals, Inc.148
  • 6.11Novartis AG150
  • 6.12Onyx Pharmaceuticals, Inc.153
  • 6.13OSI Pharmaceuticals, Inc.154
  • 6.14Pfizer155
  • 6.15Regeneron Pharmaceuticals, Inc.156
  • 6.16Roche157
  • 6.17Sanofi-Aventis161
  
  
• 7.References164
  • 7.1Online References for Cancer164
  • 7.2Print Sources165
  • 7.3Product Approvals for Cancer Indications173
  
  
  

 

INDEX OF TABLES

Table 2.1: The 646 Medicines in Development for Cancer, 200610

Table 2.2: Drug Approvals for Cancer Indications, 1996-200711

Table 3.1: Opportunities for Molecular-Targeting Therapeutics for Cancer20

Table 3.2: Top U.S. Biotechnology Companies by Market Capitalization21

Table 3.3: Top Pharmaceutical Companies by Market Capitalization21

Table 3.4: Clinical Development for some of Hoffman-La Roche Products22

Table 3.5: Global Pharmaceutical Industry R&D Spending, 1995-200628

Table 3.6: U.S. Government NIH Research Budget, 1995-200728

Table 3.7: Health Spending as Percentage of GDP by Country29

Table 3.8: Spending on Health by Country29

Table 3.9: Annual Spending on Cancer Drugs Per Person29

Table 3.10: Patients Per Cancer Specialist30

Table 3.11: World Healthcare Cancer Therapeutics Markets by Region33

Table 3.12: The Projected Growth in the U.S. Market for Cancer Therapeutics, 1998-200634

Table 3.13: The Projected Growth in the European Market for Cancer Therapeutics, 1998-200634

Table 3.14: The Projected Growth in the Japanese Market for Cancer Therapeutics, 1998-200634

Table 3.15: Cancer Vaccines Approved or in Phase III Clinical Trials49

Table 3.16: Anti-Angiogenic Drugs in Clinical Trial for Cancer51

Table 4.1: Estimates of New Cancer Cases and Deaths in the U.S. by Sex for all Cancer Sites, 200756

Table 4.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in the U.S., by Sex, 200757

Table 4.3: Estimated Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites and by Level of Economic Development, 200758

Table 4.4: Estimated Number of New Cancer Cases and Deaths by World Area, 200760

Table 4.5: Cancer Death Rates per 100,000 Population (and Rank) for all Cancer Sites by Country, 200661

Table 4.6: Genes and Cancer Risk62

Table 4.7: Carcinogens in the Workplace64

Table 5.1: Drugs Used in Bladder Cancer Therapy69

Table 5.2: Drugs in Development for Bladder Cancer71

Table 5.3: Medicines in Development for Brain Cancer72

Table 5.4: Classes of Chemotherapy Drugs Used to Treat Breast Cancer74

Table 5.5: U.S. Sales of Doxorubicin, 2001-200976

Table 5.6: New Therapeutics for Breast Cancer78

Table 5.7: Other Classes of Drugs Used to Treat Breast Cancer80

Table 5.8: Worldwide AstraZeneca\'s Nolvadex Sales, 2000-200582

Table 5.9: Aromatase Inhibitors83

Table 5.10: Worldwide Sales Estimates for Arimidex, 2000-200884

Table 5.11: Worldwide Herceptin Sales, 1999-200586

Table 5.12: Innovative Drug Therapies applied to the Breast Cancer Market Sector89

Table 5.13: Treatment Regimens for Advanced Breast Cancer89

Table 5.14: Medicines in Development for Cervical Cancer93

Table 5.15: New Therapies for Colon Cancer94

Table 5.16: Worldwide Sales for Xeloda, 2001-200597

Table 5.17: Worldwide Sales of Tomudex, 1998-200597

Table 5.18: Medicines in Development for Leukemia103

Table 5.19: Pricing of Novartis\' Gleevec in Various Strengths in the U.S.106

Table 5.20: Medicines in Development for Lymphoma109

Table 5.21: U.S. Sales of Rituxan, 1999-2005111

Table 5.22: Cytotoxics for Lung Cancer Therapy115

Table 5.23: Anti-Angiogenics for Lung Cancer115

Table 5.24: Drugs in Development for Lung Cancer120

Table 5.25: Current Therapies for Ovarian Cancer124

Table 5.26: Emerging Therapies for Ovarian Cancer125

Table 5.27: New Development Therapies for Ovarian Cancer126

Table 5.28: New Drug Types for Ovarian Cancer127

Table 5.29: Medicines in Development for Prostate Cancer133

Table 6.1: Potential Therapeutic Indications and Development Stages146

Table 6.2: Products in Clinical Development in Phase II and III (Including Additional Indications)161

Table 7.1: Drugs Currently Approved for the Treatment of Cancer166

 

Other users found this report page using the following search terms: cancer therapeutics cancer therapeutics markets sales market global doxorubicin breast companiesbreast casncer

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.